source
- STAT+: Pharma’s drug spending deflectionJob lock, surging prescription drug costs, No Surprises Act update, and more from STAT's Health Care Inc.
- MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readoutWhile MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb's Cobenfy is likely to hold its market share.